Literature DB >> 20931405

Topiramate in the treatment of alcohol dependence: a meta-analysis.

B Arbaizar1, T Diersen-Sotos, I Gómez-Acebo, J Llorca.   

Abstract

UNLABELLED: Several controlled clinical trials have studied the efficacy of topiramate in the treatment of alcoholism. In this paper, we have performed a meta-analysis of those trials in which topiramate was compared with placebo and then we reviewed its efficacy in trials in which it was compared with other drugs.
METHOD: A quantitative synthesis of data was per-formed using inverse variance weighting in a random effects model.
RESULTS: Based on three placebo-controlled trials, topiramate is more efficacious than placebo in reducing the percentage of heavy drinking days (23.2%, 95% confidence interval [CI]: 15.7 to 34.4), increasing the number of days of abstinence (mean difference: 2.9 days, 95% CI: 2.5 to 3.3),and lowering the logarithm of g-GT levels (mean difference:0.075 95% CI: 0.048 to 0.118). Two trials suggested that topiramate is also more efficacious than naltrexone, and one open-label study reported better results for disulfiram than for topiramate.
CONCLUSION: Topiramate can be used in alcohol dependence. Adverse effects such as paresthesia or insomnia should be taken into account when prescribing topiramate.Its optimal dosage requires further research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20931405

Source DB:  PubMed          Journal:  Actas Esp Psiquiatr        ISSN: 1139-9287            Impact factor:   1.196


  14 in total

1.  Receipt of Pharmacotherapy for Alcohol Use Disorder by Male Justice-Involved U.S. Veterans Health Administration Patients.

Authors:  Andrea K Finlay; Ingrid Binswanger; Christine Timko; Joel Rosenthal; Sean Clark; Jessica Blue-Howells; Jim McGuire; Hildi Hagedorn; Jessie Wong; James Van Campen; Alex H S Harris
Journal:  Crim Justice Policy Rev       Date:  2016-04-18

2.  Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs.

Authors:  Andrea K Finlay; Laura S Ellerbe; Jessie J Wong; Christine Timko; Anna D Rubinsky; Shalini Gupta; Thomas R Bowe; Jennifer L Burden; Alex H S Harris
Journal:  J Subst Abuse Treat       Date:  2017-03-10

Review 3.  Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Authors:  Patrycja Kleczkowska; Irena Smaga; Małgorzata Filip; Magdalena Bujalska-Zadrozny
Journal:  Neurotox Res       Date:  2016-08-02       Impact factor: 3.911

Review 4.  Topiramate in Alcohol Use Disorders: Review and Update.

Authors:  Riccardo Guglielmo; Giovanni Martinotti; Marianna Quatrale; Lucia Ioime; Irket Kadilli; Marco Di Nicola; Luigi Janiri
Journal:  CNS Drugs       Date:  2015-05       Impact factor: 5.749

5.  A meta-analysis of topiramate's effects for individuals with alcohol use disorders.

Authors:  Janet C Blodgett; A C Del Re; Natalya C Maisel; John W Finney
Journal:  Alcohol Clin Exp Res       Date:  2014-05-05       Impact factor: 3.455

Review 6.  Treatment of the depressed alcoholic patient.

Authors:  Jeffrey J DeVido; Roger D Weiss
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

7.  Pharmacotherapies and personalized medicine for alcohol use disorder: a review.

Authors:  Falk W Lohoff
Journal:  Pharmacogenomics       Date:  2020-08-18       Impact factor: 2.533

8.  Use of Topiramate in the Spectrum of Addictive and Eating Disorders: A Systematic Review Comparing Treatment Schemes, Efficacy, and Safety Features.

Authors:  Mikail Nourredine; Lucie Jurek; Bernard Angerville; Yannick Longuet; Julia de Ternay; Alain Derveaux; Benjamin Rolland
Journal:  CNS Drugs       Date:  2021-02-16       Impact factor: 5.749

9.  Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study.

Authors:  Thomas Paparrigopoulos; Elias Tzavellas; Dimitris Karaiskos; Georgia Kourlaba; Ioannis Liappas
Journal:  BMC Psychiatry       Date:  2011-03-14       Impact factor: 3.630

Review 10.  2012 Update in addiction medicine for the generalist.

Authors:  Darius A Rastegar; Hillary V Kunins; Jeanette M Tetrault; Alexander Y Walley; Adam J Gordon
Journal:  Addict Sci Clin Pract       Date:  2013-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.